Tumor profiling of gastric and esophageal carcinoma reveal different treatment options

Exploiting APC Function as a Novel Cancer Therapy

(2014) Alyssa Lesko et al.   CURRENT DRUG TARGETS

Molecular profiling in gastric cancer: Examining potential targets for chemotherapy

(2014) John T. Miura et al.   JOURNAL OF SURGICAL ONCOLOGY

Response to First-Line Chemotherapy in Patients with Non-Small Cell Lung Cancer According to RRM1 Expression

(2014) Xiaopeng Dong et al.   PLoS One

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

(2013) M A Warso et al.   BRITISH JOURNAL OF CANCER

Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma

(2013) Zheng Chen et al.   CANCER

Esophageal carcinoma

(2013) Patrick M. Boland et al.   CURRENT OPINION IN ONCOLOGY

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

(2012) Pasi A Jänne et al.   LANCET ONCOLOGY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY